Polish Journal of Pathology
eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2025
vol. 76
 
Share:
Send email
Share:
Original paper

Investigation of clinicopathological and prognostic association of TERT promoter mutation in non-small cell lung cancer in a Turkish population

Onur Dülger
1
,
Ilhan Yaylim
1
,
Ismail Yilmaz
2
,
Fatma Sen
3
,
Büge Öz
4

  1. Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
  2. Department of Pathology, Abdulhamid Han Research and Training Hospital, University of Health Sciences, Istanbul, Turkey
  3. Department of Medical Oncology, Avrasya Hospital, Istanbul, Turkey
  4. Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Pol J Pathol 2025; 76 (1): 38-46
DOI: https://doi.org/10.5114/pjp.2025.149380
Online publish date: 2025/04/09
Article file
- 02978 Investigation of clinicopathological.pdf  [1.04 MB]
Get citation
 
PlumX metrics:
 
1. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016; 893: 1-19.
2. Wang X, Yin H, Zhang L, et al. The construction and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small cell lung cancer. J Thorac Dis 2019; 11: 1772-1778.
3. Qiu M, Chen YB, Jin S, et al. Research on circadian clock genes in non-small-cell lung carcinoma. Chronobiol Int 2019; 36: 739-750.
4. Yu XJ, Chen G, Yang J, et al. Smoking alters the evolutionary trajectory of non-small cell lung cancer. Exp Ther Med 2019; (5): 3315-3324.
5. Nigro E, Imperlini E, Scudiero O, et al. Differentially expressed and activated proteins associated with non small cell lung cancer tissues. Respir Res 2015; 16: 74.
6. Braicu C, Zimta AA, Harangus A, et al. The function of non-coding RNAs in lung cancer tumorigenesis. Cancers (Basel) 2019; 11: 605.
7. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83: 355-367.
8. Narsule CK, Sridhar P, Nair D, et al. Percutaneous thermal ablation for stage IA non-small cell lung cancer: long-term follow-up. J Thorac Dis 2017; 9: 4039-4045.
9. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172: 523-529.
10. Tan WL, Jain A, Takano A, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol 2016; 17: e347-e362.
11. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2019; 69: 184-210.
12. Wadowska K, Bil-Lula I, Trembecki £. Genetic markers in lung cancer diagnosis: a review. Int J Mol Sci 2020; 21: 4569.
13. Dülger O, Öz B. Comparison of different ROS1 immunohistochemistry clones and consistency with fluorescence in situ hybridization results in non-small cell lung carcinoma. Balkan Med J 2023; 40: 344-350.
14. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017; 389: 299-311.
15. Planchard D, Popat S, Kerr K, et al. ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv192-iv237.
16. Yoo SS, Do SK, Choi JE, et al. TERT polymorphism rs2853669 influences on lung cancer risk in the Korean Population. J Korean Med Sci 2015; 30: 1423-1428.
17. Griewank KG, Murali R, Schilling B, et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One 2013; 8: e80354.
18. Cheng D, Zhao Y, Zhang F, et al. Engineering a humanized telomerase reverse transcriptase gene in mouse embryonic stem cells. Sci Rep 2019; 9: 9683.
19. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013; 75: 685-705.
20. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
21. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957-959.
22. Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol 2016; 40: 9-14.
23. Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 2016; 23: R143-155.
24. Powter B, Jeffreys SA, Sareen H, et al. Human TERT promoter mutations as a prognostic biomarker in glioma. J Cancer Res Clin Oncol 2021; 147: 1007-1017.
25. Yuan P, Cao JL, Abuduwufuer A, et al. Clinical characteristics and prognostic significance of TERT promoter mutations in cancer: a cohort study and a meta-analysis. PLoS One 2016; 11: e0146803.
26. Jung SJ, Kim DS, Park WJ, et al. Mutation of the TERT promoter leads to poor prognosis of patients with non-small cell lung cancer. Oncol Lett 2017; 14: 1609-1614.
27. Ma X, Gong R, Wang R, et al. Recurrent TERT promoter mutations in non-small cell lung cancers. Lung Cancer 2014; 86: 369-373.
28. Zalewska-Ziob M, Dobija-Kubica K, Biernacki K, et al. Clinical and prognostic value of hTERT mRNA expression in patients with non-small-cell lung cancer. Acta Biochim Pol 2017; 64: 641-646.
29. Pesenti C, Paganini L, Fontana L, et al. Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status. Oncotarget 2017; 8: 57134-57148.
30. Kang SY, Kim DG, Kim H, et al. Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers. BMC Med Genomics 2022; 15: 25.
31. Onder S, Ozturk Sari S, Yegen G, et al. Classic architecture with multicentricity and local recurrence, and absence of TERT promoter mutations are correlates of BRAF V600E harboring pediatric papillary thyroid carcinomas. Endocrin Pathol 2016; 27: 153-161.
32. Yilmaz I, Erkul BE, Sari SO, et al. Promoter region mutations of the telomerase reverse transcriptase (TERT) gene in head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2020; 130: 63-70.
33. Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet 2019; 20: 299-309.
34. Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene 2019; 38: 6172-6183.
35. Razis E, Kotoula V, Koliou GA, et al. Is there an independent role of TERT and NF1 in high grade gliomas? Transl Oncol 2020; 13: 346-354.
36. Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 2015; 26: 1877-1883.
Copyright: © 2025 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.